Sugi Predict

Sugi Predict / Compounds / SCHEMBL298491

SCHEMBL298491

SCHEMBL298491

COc1ccnc2[nH]ccc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 2/20 0.60
▸ PRKCI P41743 3/20 0.53
▸ AXL P30530 1/20 0.53
▸ AURKB Q96GD4 3/20 0.47
▸ IKBKB O14920 1/20 0.47
▸ CHUK O15111 1/20 0.47
▸ DAPK3 O43293 1/20 0.47
▸ JAK2 O60674 1/20 0.47
▸ PRKD3 O94806 1/20 0.47
▸ MAP4K4 O95819 1/20 0.47
▸ PAK4 O96013 1/20 0.47
▸ CSF1R P07333 1/20 0.47
▸ RET P07949 1/20 0.47
▸ IGF1R P08069 1/20 0.47
▸ FGFR1 P11362 1/20 0.47
▸ PRKACA P17612 1/20 0.47
▸ FLT1 P17948 1/20 0.47
▸ LTK P29376 1/20 0.47
▸ GRK5 P34947 1/20 0.47
▸ KDR P35968 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29424797 1.00 BRD4 (0.60) BRD4PRKCIAXLAURKBIKBKB
SCHEMBL30669883 0.84 BRD4 (0.52) BRD4PRKCIAXLAURKBIKBKB
SCHEMBL2992617 0.81 NUDT1 (0.55) BRD4PRKCIAXLAURKBIKBKB
SCHEMBL12605521 0.81 CCNK (0.51) BRD4PRKCIAXLAURKBIKBKB
SCHEMBL2986157 0.80 CIT (0.50) BRD4PRKCIAXLAURKBIKBKB
SCHEMBL30461709 0.79 NUDT1 (0.52) BRD4PRKCIAXLAURKBIKBKB
SCHEMBL2988049 0.79 NUDT1 (0.52) BRD4PRKCIAXLAURKBIKBKB
SCHEMBL10125070 0.79 BRD4 (0.66) BRD4PRKCIAURKBIKBKBCHUK
SCHEMBL858602 0.79 BRD4 (0.62) BRD4PRKCIAURKBIKBKBCHUK
SCHEMBL29120136 0.78 PRKCI (0.50) BRD4PRKCIAXLAURKBIKBKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117903130-A Synthesis method of 4-hydroxy-7-azaindole 苏州艾缇克药物化学有限公司 2024-04-19 — — CN claimed
EP-4692089-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AS AAK1 INHIBITOR Alicorn Pharmaceutical Co., Ltd. (CN) 2026-02-11 — — EP disclosed
US-20250361233-A1 Compounds For Activating Serotonin Receptor Psylo Pty Ltd (AU) 2025-11-27 — — US disclosed
US-12415804-B2 Compounds for activating a serotonin receptor Psylo Pty Ltd (AU) 2025-09-16 — — US disclosed
US-20250206739-A1 Compounds Psylo Pty Ltd (AU) 2025-06-26 — — US disclosed
US-20250163044-A1 COMPOUNDS Psylo Pty Ltd (AU) 2025-05-22 — — US disclosed
US-20250041319-A1 BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS RIBOSCIENCE LLC 2025-02-06 — — US disclosed
EP-4452979-A1 COMPOUNDS Psylo Pty Ltd (AU) 2024-10-30 — — EP disclosed
CN-118772152-A Azacyclic compounds as AAK1 inhibitors 艾立康药业股份有限公司 2024-10-15 — — CN disclosed
WO-2024207945-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AS AAK1 INHIBITOR 艾立康药业股份有限公司 2024-10-10 — — WO disclosed
US-20040044025-A1 Processes for the preparation of antiviral 7-azaindole derivatives BRISTOL-MYERS SQUIBB COMPANY 2004-03-04 — — US disclosed
US-20040023982-A1 Antiviral azaindole derivatives VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2004-02-05 — — US disclosed
US-20030181463-A1 Antiviral azaindole derivatives VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2003-09-25 — — US disclosed
EP-1307454-A1 DERIVATIVES OF VARIOLIN B Universidad de Barcelona (ES) 2003-05-07 — — EP disclosed
WO-2003000688-A1 AZAINDOLES AVENTIS PHARMA LIMITED (GB) 2003-01-03 — — WO disclosed
EP-1257276-A1 ANTIVIRAL AZAINDOLE DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY (US) 2002-11-20 — — EP disclosed
US-20020119982-A1 Antiviral azaindole derivatives VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2002-08-29 — — US disclosed
US-20020061892-A1 Antiviral azaindole derivatives VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2002-05-23 — — US disclosed
WO-2002012240-A1 DERIVATIVES OF VARIOLIN B UNIVERSIDAD DE BARCELONA (ES) 2002-02-14 — — WO disclosed
WO-2001062255-A1 ANTIVIRAL AZAINDOLE DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY (US) 2001-08-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020119982-A1 Antiviral azaindole derivatives ZC3HAV1, MAVS, AZI2 BRD4 82/4885PRKCI 3590/4885AXL 4547/4885
US-20250206739-A1 Compounds NLN, SLC18A2, PYGB BRD4 1783/4885PRKCI 3462/4885AXL 4487/4885
US-20020061892-A1 Antiviral azaindole derivatives ZC3HAV1, MAVS, AZI2 BRD4 82/4885PRKCI 3590/4885AXL 4547/4885
US-12415804-B2 Compounds for activating a serotonin receptor HTR2C, HTR6, HTR2A BRD4 2971/4885PRKCI 2697/4885AXL 2597/4885
US-20040044025-A1 Processes for the preparation of antiviral 7-azaindole derivatives IMPDH1, MAVS, ZC3HAV1 BRD4 1779/4885PRKCI 2801/4885AXL 4103/4885
US-20250361233-A1 Compounds For Activating Serotonin Receptor HTR2C, HTR2A, HTR6 BRD4 3045/4885PRKCI 2973/4885AXL 2342/4885
US-20250041319-A1 BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS ENPP1, ENPP3, SMPD1 BRD4 1614/4885PRKCI 839/4885AXL 4496/4885
US-20250163044-A1 COMPOUNDS NLN, SLC18A2, PYGB BRD4 1783/4885PRKCI 3462/4885AXL 4487/4885
US-20040023982-A1 Antiviral azaindole derivatives ZC3HAV1, MAVS, EIF2AK2 BRD4 100/4885PRKCI 3421/4885AXL 4545/4885
US-20030181463-A1 Antiviral azaindole derivatives ZC3HAV1, MAVS, AZI2 BRD4 82/4885PRKCI 3590/4885AXL 4547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.